View all press releases

Pilot Study to Investigate a Cannabinoid Derived Drug in Dogs


Tetra Bio-Pharma and Panag Pharma Advance their Veterinary Drug Pipeline 

ORLEANS, Ontario, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or “TBP”) (TSX VENTURE: TBP) (OTCQB: TBPMF) and Panag Pharma Inc. (“Panag”) today announced the submission of a clinical research application to the Veterinary Drugs Directorate at Health Canada. This first of a kind veterinary study will examine the use of a cannabinoid-based drug to treat ocular pain and inflammation in canines. The pilot study will be led by veterinary ocular care specialists. 

“Several companies are marketing cannabis-based treatments for aliments in companion animals, but there is a major gap in understanding the safety and efficacy of these drugs,” said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma. “This study demonstrates our commitment to becoming a world leader in the field of cannabinoid-based therapies for vision health. Tetra continues to adhere to an evidence-based drug development model, consistent with bringing novel, efficacious and safe drug products to market, including the veterinary market. We look forward to launching this trial to investigate the use of cannabinoids to treat eye pain and inflammation in dogs.” 

In addition to the pharmaceutical and natural health products markets, Tetra will also launch trials in the companion animal market.  If approved, these products will be destined for global sales. At present, world-wide revenues derived from the companion animal market exceeded $30 billion in 2017, and this is expected to grow to $41 billion by 2024.   

About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit:

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research and development strategies, including this trial, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.                                     

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard 
Executive Vice-President Corporate Development and Licensing
Media Contact  
energi PR  
Carol Levine  Stephanie Engel
514-288-8500 ext. 226 416-425-9143 ext. 209 


Source: Tetra Bio-Pharma Inc

Categories: Press Releases
View all press releases